SCHEMBL12426423

SCHEMBL12426423

CC1CCc2nc(-c3cc(Cl)ccc3F)nc(Cl)c21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.35
PRKD3 O94806 1/20 0.34
TGFBR1 P36897 1/20 0.34
PRKD1 Q15139 1/20 0.34
PRKD2 Q9BZL6 1/20 0.34
GRM2 Q14416 2/20 0.32
TYMS P04818 2/20 0.32
IDH2 P48735 1/20 0.32
PDE4D Q08499 2/20 0.32
HTR2B P41595 1/20 0.32
CHRM1 P11229 1/20 0.31
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31
PLAT P00750 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.30
SLC22A1 O15245 1/20 0.30
ABCB11 O95342 1/20 0.30
CYP3A4 P08684 1/20 0.30
DRD3 P35462 1/20 0.30
OPRK1 P41145 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12426424 0.87 IDH1 (0.34) IDH1PRKD3TGFBR1PRKD1PRKD2
SCHEMBL2200301 0.87 IDH1 (0.34) IDH1PRKD3TGFBR1PRKD1PRKD2
SCHEMBL2201678 0.87 IDH1 (0.34) IDH1PRKD3TGFBR1PRKD1PRKD2
SCHEMBL12426420 0.87 IDH1 (0.34) IDH1PRKD3TGFBR1PRKD1PRKD2
SCHEMBL2201640 0.76 TGFBR1 (0.41) PRKD3TGFBR1PRKD1PRKD2CYP3A4
SCHEMBL12426422 0.76 TGFBR1 (0.41) PRKD3TGFBR1PRKD1PRKD2CYP3A4
SCHEMBL12510114 0.74 NISCH (0.35) IDH1IDH2
SCHEMBL12426347 0.73 ACHE (0.44) PRKD3TGFBR1PRKD1PRKD2CHRM1
SCHEMBL2200699 0.73 SOS1 (0.45) CHRM1
SCHEMBL12426215 0.72 TGFBR1 (0.51) TGFBR1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977342-B2 HCV inhibiting bi-cyclic pyrimidines TIBOTEC-VIRCO VIROLOGY BVBA (BE) 2011-07-12 US disclosed
US-7977342-B2 HCV inhibiting bi-cyclic pyrimidines TIBOTEC-VIRCO VIROLOGY BVBA (BE) 2011-07-12 US disclosed
US-20070155716-A1 HCV INHIBITING BI-CYCLIC PYRIMIDINES TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-07-05 US disclosed
US-20070155716-A1 HCV INHIBITING BI-CYCLIC PYRIMIDINES TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-07-05 US disclosed
US-7223766-B2 Bi-cyclic pyrimidine inhibitors of TGFβ SCIOS, INC. (US) 2007-05-29 US disclosed
US-7223766-B2 Bi-cyclic pyrimidine inhibitors of TGFβ SCIOS, INC. (US) 2007-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155716-A1 HCV INHIBITING BI-CYCLIC PYRIMIDINES UMPS, NUDT1, PNP IDH1 256/4885PRKD3 3048/4885TGFBR1 3900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.